dawn-bio

dawn-bio is a private, pre-revenue biotech company based in Vienna, Austria, developing a novel platform for in vitro fertilization (IVF). The company's core technology is a human stem-cell based embryo and implantation model (blastoid technology) that allows for unprecedented research into early human development. Its initial goal is to develop products that enable IVF clinics to improve embryo quality and quantity, addressing the high failure rates in current treatments. The team combines deep scientific expertise in stem cell biology and embryology with seasoned pharmaceutical and biotech entrepreneurship.

Proprietary human stem-cell based embryo and implantation model (blastoid technology) used to decode biological signals for embryo development and translate findings into products for IVF clinics.

dawn-bio competes in the broader IVF market dominated by large medtech companies (e.g., CooperSurgical, Vitrolife, Merck) that supply culture media and incubators. Its direct competitors are likely other early-stage biotechs applying systems biology or novel models to improve embryo selection or culture, but its focus on using blastoids to enhance embryo creation is a distinctive and potentially disruptive approach.